In Vivo Selection and Validation of Liver-Specific Ligands Using a New T7 Phage Peptide Display System
Authors:
Open Access
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 14 (6) , 357-369
Abstract
In vivo phage display is a powerful source of new peptide ligands for specific organ targeting by drugs and gene therapy vectors. Since the introduction of this methodology a decade ago, a number of peptides that preferentially react with organ-specific endothelium and parenchymal markers have been selected. One organ that has been conspicuously missing from these selection studies is the liver, which possesses a multitude of acquired and hereditary disorders and represents a highly important therapeutic target. Herein, we set out to fill this gap by introducing a novel peptide display system containing cloned sequences in the tail fiber protein (p17) of phage T7. The p17 display effectively avoids the innate immune system and is well suited both for selection of new liver-specific ligands and for validation of protein sequences that have been implicated in liver targeting by the use of conventional biochemical methods.Keywords
This publication has 21 references indexed in Scilit:
- Bioactive Peptides from LibrariesChemistry & Biology, 2005
- Sequence‐specific binding of normal serum immunoglobulin M to exposed protein C‐terminiImmunology, 2004
- Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectorsMolecular Therapy, 2003
- Uptake and Processing of Modified Bacteriophage M13 in Mice: Implications for Phage DisplayVirology, 2002
- Specific Recognition of Protein Carboxy-Terminal Sequences by Natural IgM Antibodies in Normal SerumMolecular Therapy, 2001
- The Interactions of Peptides with the Innate Immune System Studied with Use of T7 Phage Peptide DisplayMolecular Therapy, 2000
- Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.Journal of Clinical Investigation, 1998
- Possible Functional Interactions of Apolipoprotein B-100 Segments That Associate With Cell Proteoglycans and the ApoB/E ReceptorArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Organ targeting In vivo using phage display peptide librariesNature, 1996
- Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice.Journal of Clinical Investigation, 1994